Becton, Dickinson and Co ( (BDX) ) has released its Q4 earnings. Here is a breakdown of the information Becton, Dickinson and Co presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Becton, Dickinson and Co (BD) is a global leader in medical technology, specializing in advancing healthcare through innovative solutions in diagnostics, medical discovery, and care delivery. The company operates across various sectors, including BD Medical, BD Life Sciences, and BD Interventional.
In its fiscal 2025 fourth quarter and full-year financial results, BD reported a significant increase in revenue, with Q4 revenue reaching $5.9 billion, an 8.3% increase from the previous year. The company’s adjusted diluted EPS for the full year grew by 9.6% to $14.40, highlighting robust financial performance despite a slight decrease in GAAP EPS.
Key highlights from the report include the launch of AI-enabled solutions in the BD Medical segment and a strategic partnership with Henry Ford Health to enhance pharmacy automation. The BD Interventional segment achieved a milestone with the Rotarex™ Catheter System, while BD Life Sciences celebrated manufacturing excellence and introduced new solutions for HPV testing. The company also returned $2.2 billion to shareholders through dividends and share repurchases.
Looking ahead, BD remains optimistic about its growth trajectory, with plans to combine its Biosciences and Diagnostic Solutions business with Waters Corporation by early 2026. The company anticipates continued revenue growth in fiscal 2026, driven by strategic initiatives and market expansion efforts. BD’s management is committed to delivering long-term value by focusing on high-growth markets and operational excellence.